{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:50:43Z","timestamp":1791388243611,"version":"4.3.3"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jbspin.2026.106068","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:08:15Z","timestamp":1777590495000},"page":"106068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescription of targeted therapies in patient with a history of cancer"],"prefix":"10.1016","volume":"93","author":[{"given":"Eden","family":"Sebbag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jbspin.2026.106068_bib0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jbspin.2026.106068_bib0320","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jbspin.2026.106068_bib0325","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2026.106068_bib0330","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.jbspin.2026.106068_bib0335","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.semarthrit.2007.08.006","article-title":"Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population","volume":"37","author":"Ab\u00e1solo","year":"2008","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jbspin.2026.106068_bib0340","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrc1782","article-title":"Paradoxical roles of the immune system during cancer development","volume":"6","author":"de Visser","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.jbspin.2026.106068_bib0345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41584-025-01235-8","article-title":"Treating inflammatory arthritis in individuals with concomitant cancer","volume":"21","author":"Suarez-Almazor","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2026.106068_bib0350","article-title":"2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer","author":"Sebbag","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jbspin.2026.106068_bib0355","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jbspin.2026.106068_bib0360","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9255","key":"10.1016\/j.jbspin.2026.106068_bib0365","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jbspin.2026.106068_bib0370","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10555-006-9005-3","article-title":"TNF-alpha in promotion and progression of cancer","volume":"25","author":"Balkwill","year":"2006","journal-title":"Cancer Metastasis Rev"},{"issue":"Pt 1","key":"10.1016\/j.jbspin.2026.106068_bib0375","first-page":"1","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem J"},{"issue":"10","key":"10.1016\/j.jbspin.2026.106068_bib0380","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jbspin.2026.106068_bib0385","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.it.2014.09.006","article-title":"Tertiary lymphoid structures in cancer and beyond","volume":"35","author":"Dieu-Nosjean","year":"2014","journal-title":"Trends Immunol"},{"issue":"3","key":"10.1016\/j.jbspin.2026.106068_bib0390","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2004.07.013","article-title":"IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer","volume":"118","author":"Greten","year":"2004","journal-title":"Cell"},{"issue":"7007","key":"10.1016\/j.jbspin.2026.106068_bib0395","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature02924","article-title":"NF-kappaB functions as a tumour promoter in inflammation-associated cancer","volume":"431","author":"Pikarsky","year":"2004","journal-title":"Nature"},{"issue":"10105","key":"10.1016\/j.jbspin.2026.106068_bib0400","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jbspin.2026.106068_bib0405","doi-asserted-by":"crossref","first-page":"e002465","DOI":"10.1136\/rmdopen-2022-002465","article-title":"Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking","volume":"8","author":"Chatzidionysiou","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2026.106068_bib0410","doi-asserted-by":"crossref","first-page":"100768","DOI":"10.1016\/j.lanepe.2023.100768","article-title":"Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study","volume":"35","author":"Beydon","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.jbspin.2026.106068_bib0415","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.berh.2017.08.003","article-title":"Genetic and environmental risk factors for rheumatoid arthritis","volume":"31","author":"Deane","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.jbspin.2026.106068_bib0420","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.gtc.2021.12.011","article-title":"Intestinal cancer and dysplasia in Crohn's disease","volume":"51","author":"Friedberg","year":"2022","journal-title":"Gastroenterol Clin North Am"},{"issue":"4","key":"10.1016\/j.jbspin.2026.106068_bib0425","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jbspin.2026.106068_bib0430","doi-asserted-by":"crossref","first-page":"1571700","DOI":"10.3389\/fimmu.2025.1571700","article-title":"Cancer in connective tissue disease","volume":"16","author":"Tonutti","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jbspin.2026.106068_bib0435","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren's syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.jbspin.2026.106068_bib0440","doi-asserted-by":"crossref","first-page":"105176","DOI":"10.1016\/j.jbspin.2021.105176","article-title":"Inflammation-targeted therapies and cancer","volume":"88","author":"Kedra","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"10","key":"10.1016\/j.jbspin.2026.106068_bib0445","doi-asserted-by":"crossref","first-page":"e1913102","DOI":"10.1001\/jamanetworkopen.2019.13102","article-title":"Risk of infections and cancer in patients with rheumatologic diseases receiving interleukin inhibitors: a systematic review and meta-analysis","volume":"2","author":"Bilal","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.jbspin.2026.106068_bib0450","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"74","author":"Mercer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jbspin.2026.106068_bib0455","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.jbspin.2026.106068_bib0460","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13075-022-02868-w","article-title":"The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study","volume":"24","author":"Choi","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.jbspin.2026.106068_bib0465","doi-asserted-by":"crossref","first-page":"e2446336","DOI":"10.1001\/jamanetworkopen.2024.46336","article-title":"Use of biologic or targeted synthetic disease-modifying antirheumatic drugs and cancer risk","volume":"7","author":"Sendaydiego","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jbspin.2026.106068_bib0470","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"Aaltonen","year":"2015","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jbspin.2026.106068_bib0475","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S2468-1253(19)30362-0","article-title":"Anti-tumour necrosis factor-\u03b1 therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study","volume":"5","author":"Waljee","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jbspin.2026.106068_bib0480","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jbspin.2026.106068_bib0485","doi-asserted-by":"crossref","first-page":"166685","DOI":"10.1016\/j.jmb.2020.10.019","article-title":"Regulatory B cells and T cell regulation in cancer","volume":"433","author":"Horii","year":"2021","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.jbspin.2026.106068_bib0490","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1038\/s41467-019-12160-2","article-title":"B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma","volume":"10","author":"Griss","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jbspin.2026.106068_bib0495","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/key352","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study","volume":"58","author":"Montastruc","year":"2019","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.jbspin.2026.106068_bib0500","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","article-title":"Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study","volume":"21","author":"Simon","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.jbspin.2026.106068_bib0505","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/rheumatology\/keab570","article-title":"Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice","volume":"61","author":"Huss","year":"2022","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.jbspin.2026.106068_bib0510","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study","volume":"59","author":"de Germay","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.jbspin.2026.106068_bib0515","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-019-1921-z","article-title":"Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study","volume":"21","author":"Ozen","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2026.106068_bib0520","doi-asserted-by":"crossref","first-page":"152240","DOI":"10.1016\/j.semarthrit.2023.152240","article-title":"Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study","volume":"64","author":"Simon","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jbspin.2026.106068_bib0525","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.jbspin.2026.106068_bib0530","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/rheumatology\/keae140","article-title":"Cancer risk with tocilizumab\/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study","volume":"64","author":"Westermann","year":"2025","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.jbspin.2026.106068_bib0535","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2026.106068_bib0540","series-title":"Janus kinase inhibitors (JAKi)","year":"2022"},{"key":"10.1016\/j.jbspin.2026.106068_bib0545","unstructured":"Schaefer M, Purschke A, Zietemann V, Rudi T, Meissner Y, Richter A, et al. Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register. Ann Rheum Dis."},{"issue":"5","key":"10.1016\/j.jbspin.2026.106068_bib0550","doi-asserted-by":"crossref","first-page":"105900","DOI":"10.1016\/j.jbspin.2025.105900","article-title":"Risk of cancer in patients with rheumatoid arthritis under tocilizumab: data from the French national registry REGATE","volume":"92","author":"Morel","year":"2025","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.jbspin.2026.106068_bib0555","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.jbspin.2026.106068_bib0560","first-page":"643","article-title":"Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer","volume":"84","author":"Sebbag","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.jbspin.2026.106068_bib0565","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/art.39738","article-title":"Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory Bowel disease: a cohort study","volume":"68","author":"Mamtani","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.jbspin.2026.106068_bib0570","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/annrheumdis-2014-205745","article-title":"TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study","volume":"74","author":"Raaschou","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jbspin.2026.106068_bib0575","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of non-melanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and non-melanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jbspin.2026.106068_bib0580","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/rheumatology\/kew314","article-title":"The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis","volume":"55","author":"Silva-Fern\u00e1ndez","year":"2016","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.jbspin.2026.106068_bib0585","doi-asserted-by":"crossref","first-page":"291","DOI":"10.7326\/M17-2812","article-title":"Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study","volume":"169","author":"Raaschou","year":"2018","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jbspin.2026.106068_bib0590","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"Aaltonen","year":"2015","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jbspin.2026.106068_bib0595","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.jbspin.2026.106068_bib0600","doi-asserted-by":"crossref","first-page":"e005247","DOI":"10.1136\/rmdopen-2024-005247","article-title":"Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study","volume":"11","author":"Westermann","year":"2025","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.jbspin.2026.106068_bib0605","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s12282-024-01618-x","article-title":"Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors","volume":"31","author":"Ruiz","year":"2024","journal-title":"Breast Cancer"},{"issue":"5","key":"10.1016\/j.jbspin.2026.106068_bib0610","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S2665-9913(24)00379-5","article-title":"Survival in patients with rheumatoid arthritis and recently diagnosed early-stage colorectal, lung, or prostate cancer receiving tumour necrosis factor inhibitors: a retrospective cohort study","volume":"7","author":"Ruiz","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"10.1016\/j.jbspin.2026.106068_bib0615","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"10.1016\/j.jbspin.2026.106068_bib0620","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X26000370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X26000370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:55:12Z","timestamp":1791384912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X26000370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1297319X26000370"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2026.106068","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescription of targeted therapies in patient with a history of cancer","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2026.106068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"106068"}}